Hyman DM, Willis T, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol 35, 2017 (suppl; abstr LBA2501).
Baricitinib bij juveniele idiopathische artritis: JUVE-BASIS
dec 2023 | Arthritis psoriatica, Artritis, JIA